Description of the medicine: Distigmine bromide (Distigmine bromide)

DISTIMMINE Bromide (Distigmine bromide) *. 3-Oxy-1-methylpyridinium hexamethylene-bis (N-methylcarbamate) dibromide.

Synonyms: Ubretid, Hexfmarium bromide, Ubretid, Ubretil.

White powder, soluble in water.

It is an inhibitor of long-acting cholinesterase.

Applied for the prevention and therapy of postoperative intestinal atony, atony of the urinary bladder, with an increase in the amount of residual urine in patients with neurogenic disorders of urination, myasthenia and other indications for the use of anticholinesterase drugs (see Proserin, Oxazil) and holipomimetics (see Acekledin).

Assign inside and intramuscularly. Inside give, starting with 0.5 mg (1 tablet) per day, then depending on the effectiveness and tolerability of the drug, increase the dose to 2 tablets per day or reduce to 1 tablet 1 time per 2 to 3 days. Take in the morning on an empty stomach (1/2 h before breakfast).

In myasthenia gravis, the doses can be significantly increased provided that the portability and effectiveness are carefully monitored.

Intramuscular injection of 0.5 mg (1 ml of 0.05% solution). Repeated injections are done no earlier than 24 hours after the first injection. If you need long-term treatment, two to three-day breaks are recommended.

Possible side effects, precautions and contraindications are the same as for proserine and other similar anticholinesterase drugs.

Forms of release: tablets of 0.5 mg; 0.05% solution in ampoules of 1 ml (0.5 mg).